Numerous studies have shown that in clinical applications, SCD1 inhibitors (thiazol-4-acetic acid derivatives) have therapeutic potential for obesity, cancer and diabetes, but it may produce associated clinical adverse reactions (Iida et al., 2018). The gene discussed is SCD; the disease is obesity due to melanocortin 4 receptor deficiency.